<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2902245007
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DUCRESSA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXAMETHASONE,LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Tubilux Pharma S.p.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Tubilux Pharma S.p.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1022]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Al Hamaed medical company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Santen Oy
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What kind of medicine is it and how does it work</strong></p><p>Ducressa is an eye drops solution that contains dexamethasone and levofloxacin.&nbsp;</p><p>Dexamethasone is a corticosteroid, it has an anti-inflammatory action (stopping symptoms like pain, heat, swelling and redness).</p><p>Levofloxacin is an antibiotic of the type called fluoroquinolones (sometimes shortened to quinolones). It works by killing some types of bacteria that can cause infections.</p><p>&nbsp;</p><p><strong>What is your medicine for</strong></p><p>Ducressa is used to prevent and treat inflammation and prevent possible infection of the eye after cataract surgery in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Ducressa</strong><strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to levofloxacin (or other quinolones) or dexamethasone (or other corsticosteroids) or any of the other ingredients of Ducressa (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suffering from an eye infection that you are not using medicine for including viral (like herpes simplex, keratitis or varicella), fungal infections and tuberculosis of the eye.</p><p>You could have an infection if you have a sticky discharge from your eye or if you have a red eye that has not been seen by a doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before using Ducressa:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using any other antibiotic treatment, including oral antibiotics. As with other anti-infectives, prolonged use may induce antibiotic resistance with the result of overgrowth of pathogenic microorganisms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from high pressure in the eye or if you have already had high pressure in the eye after using an eye steroid medicine. You are at risk of having this again if you use Ducressa. If you suffer from high pressure in the eye tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have glaucoma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have visual disturbance or blurred vision.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using ocular NSAIDs (Nonsteroidal Anti Inflammatory Drugs) see section &ldquo;Other medicines and Ducressa.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a disorder causing a thinning of the eye tissues because prolonged steroid treatments may cause further thinning and possible perforation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are diabetic.</p><p><strong>&nbsp;</strong></p><p><strong>Important information if you wear contact lenses</strong></p><p>After cataract surgery you should not wear contact lenses for the whole duration of therapy with Ducressa.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Ducressa is not recommended for children and adolescents below 18&nbsp;years due to a lack of data on safety and efficacy in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Ducressa</strong></p><p>Tell your doctor or pharmacist</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using, have recently used or might use any other medicines, including medicines obtained without a prescription.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are applying any other type of eye drop or eye ointment before you start to use Ducressa (see section 3 &ndash; How to use Ducressa).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using ocular NSAIDs (used against pain and inflammation in the eye) like ketorolac, diclofenac, bromfenac and nepafenac. Simultaneous use of ocular steroids and ocular NSAIDs may increase the potential for healing problems in your eye.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using ritonavir or cobicistat (used in HIV treatment), as these may increase the amount of dexamethasone in the blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are using probenecid (to treat gout), cimetidine (to treat stomach ulcer) and cyclosporin (to prevent transplant rejection) as they may change absorption and metabolism of levofloxacin.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Ducressa should not be used during pregnancy or breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>If you experience temporary blurred vision after using this medicine for a short time, you should not drive or operate machinery until your vision is clear.</p><p><strong>&nbsp;</strong></p><p><strong>Ducressa contains phosphate buffer</strong></p><p>Ducressa contains 4.01 mg phosphates per ml, corresponding to 0.12 mg per drop. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphate may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment. Talk with your doctor who may prescribe you a phosphate-free treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Ducressa contains benzalkonium chloride</strong></p><p>Ducressa contains 0.05 mg benzalkonium chloride per ml corresponding to 0.0015 mg per drop.</p><p>&nbsp;</p><p>Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using Ducressa, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Ducressa exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is 1 drop in the affected eye every 6 hours. The maximum dose is 4 drops per day. The usual total treatment course with Ducressa is 7 days, followed, if deemed necessary by the doctor, by another 7 days of steroid eye drops.</p><p>&nbsp;</p><p>Your doctor will advise you how long to apply the drops.</p><p>&nbsp;</p><p>If you are putting any other medicine in your eye, you should wait at least 15 minutes between applying the different types of drops. Eye ointments should be used last.</p><p>&nbsp;</p><p><strong>Instruction for use:</strong></p><p>If possible, ask someone else to apply the drops for you. Ask them to read these instructions with you before applying the drops.</p><p>&nbsp;</p><p>1) Wash carefully your hands (picture 1).</p><p>2) Open the bottle. <strong>Remove the loose collar from the cap when the bottle is first opened.</strong></p><p>Take special care that the tip of the dropper bottle does not touch your eye, the skin around your eye or your fingers.</p><p>3) Twist off the bottle cap. Hold the bottle pointing down, between your thumb and fingers.</p><p>4) Pull down your lower eyelid with a finger, until there is a &lsquo;pocket&rsquo; between the eyelid and your&nbsp; eye. The drop will go in here (picture 2).</p><p>5) Tilt your head back and bring the bottle tip close to the eye and squeeze the bottle gently in the middle and let a drop fall into your eye (picture 3). Please note that there might be a few seconds&nbsp; delay between squeezing and the drop coming out. Do not squeeze too hard.</p><p>6) After using Ducressa press a finger into the corner of your eye by the nose. This helps to stop the medicine getting into the rest of the body (picture 4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>If a drop misses your eye, try again. Put the bottle cap firmly back on immediately after use.&nbsp;</p><p>&nbsp;</p><p><strong>If you use more Ducressa than you should</strong></p><p>If you use more of Ducressa than you should it can be washed out with warm water.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to use Ducressa </strong></p><p>If you forget to use Ducressa, do not worry, just use it as soon as possible. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Ducressa </strong></p><p>If you stop using Ducressa earlier than instructed, tell your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Ducressa can cause side effects, although not everybody gets them. Most side effects are not serious and affect only the eye.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rarely Ducressa can cause severe allergic reactions (anaphylactic reactions), accompanied by swelling and tightness in the throat and breathing difficulties.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop using Ducressa and contact your doctor immediately if any of these symptoms occurs.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendon swelling and rupture have happened in people taking oral or intravenous fluoroquinolones, particularly in older patients and in those treated concurrently with corticosteroids. Stop taking Ducressa if you develop pain or swelling of the tendons (tendinitis).</p><p>&nbsp;</p><p><strong>You may also experience some or all of the following effects in your eye(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high pressure in the eye.</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discomfort, stinging or irritation, burning, itching in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred or decreased vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mucus in the eye.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corneal healing which takes longer than expected</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal sensation in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased tearing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry and tired eye&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; brighter vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or redness (bloodshot eyes) of the front covering of the eye (conjunctivae)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or redness of the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sticky eyelids.</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in pupil size</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drooping eyelids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; setting of calcium on the surface of the eye (calcification of cornea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tears and a sandy sensation in your eye (crystalline keratopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the thickness of the surface of the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcer on the surface of the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small holes on the surface of the eye (perforation of the cornea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the surface of the eye (corneal oedema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eye which causes pain and redness (uveitis).</p><p>&nbsp;</p><p><strong>You may experience effects in other areas of your body including:</strong></p><p>&nbsp;</p><p><strong>Uncommon (</strong>may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alteration of the taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pruritus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stuffed or runny nose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as skin rash.</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial swelling.</p><p>&nbsp;</p><p><strong>Unknown</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction of adrenal gland function, which could be shown by low blood sugar, dehydratation, weight loss and feeling confused about where you are.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormone problems: growth of extra body hair (particularly in women), muscle weakness and wasting, purple stretch marks on body skin, increased blood pressure, irregular or missing periods, changes in the levels of protein and calcium in your body, stunted growth in children and teenagers and swelling and weight gain of the body and face (called &lsquo;Cushing&rsquo;s syndrome&#39;).</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 30 &deg;C.</p><p>&nbsp;</p><p>Do not use Ducressa after the expiry date which is stated on the bottle label and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use Ducressa if you notice that the plastic ring around the cap and neck is missing or broken before you start a new bottle.</p><p>&nbsp;</p><p>Keep the bottle tightly closed. To prevent infections, you must throw away the bottle 28 days after you first opened it, and use a new bottle.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; The active substances are dexamethasone as sodium phosphate and levofloxacin as hemihydrate. &nbsp;Each millilitre of solution contains 1 mg of dexamethasone and 5 mg of levofloxacin.</p><p>-&nbsp; The other ingredients are sodium dihydrogen phosphate monohydrate, disodium phosphate dodecahydrate<em>, </em>sodium citrate<em>, </em>benzalkonium chloride, sodium hydroxide /hydrochloric acid (as pH adjuster), water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ducressa is a clear, greenish-yellow solution practically free from particles, even if expelled drops appear clear and colourless. It is supplied in a pack containing one 5 ml white plastic bottle with white dropper. The plastic bottle is closed with a screw cap.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>&nbsp;Santen Oy</p><p>&nbsp;Niittyhaankatu 20, 33720 Tampere, Finland</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Manufacturer</strong></p><p>&nbsp;Tubilux Pharma S.p.A.</p><p>&nbsp;Via Costarica 20/22, 00071 Pomezia (RM), Italy</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Manufacturer responsible for batch release</strong></p><p>&nbsp;Santen&nbsp;Oy</p><p>&nbsp;Kelloportinkatu 1, Tampere, 33100, Finland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو نوع الدواء وكيف يعمل</strong></p><p dir="RTL">دوكريسا عبارة عن قطرات للعين يحتوي على ديكساميثازون و الليفوفلوكساسين .</p><p dir="RTL">ديكساميثازون هو كورتيكوستيرويد، وله تأثير مضاد للالتهابات (يوقف أعراض الألم والحرارة والتورم والاحمرار).</p><p dir="RTL">الليفوفلوكساسين مضاد حيوي من النوع المسمى الفلوروكينولونات (يختصر أحيانًا إلى الكينولونات). وهو يعمل عن طريق قتل بعض أنواع البكتيريا التي يمكن أن تسبب الالتهابات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>فيما يستخدم هذا الدواء</strong></p><p dir="RTL">يستخدم دوكريسا لمنع وعلاج الالتهاب ومنع العدوى المحتملة للعين بعد جراحة إعتام عدسة العين عند البالغين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم دوكريسا في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه الليفوفلوكساسين (أو الكينولونات الأخرى) أو الديكساميثازون (أو الكورستكوستيرويدات الأخرى) أو أي من المكونات الأخرى لدوكريسا (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من عدوى بالعين لا تستعمل دواء لها بما في ذلك الفيروسية (مثل الهربس البسيط، التهاب القرنية أو الجدري المائي)، والالتهابات الفطرية وتدرن العين.</p><p dir="RTL">قد تصاب بالعدوى إذا كان لديك إفرازات لزجة من عينك أو إذا كانت عينك حمراء ولم يراها الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل استخدام دوكريسا:</p><p dir="RTL">-&nbsp;&nbsp; - إذا كنت تستخدم أي مضاد حيوي آخر، بما في ذلك المضادات الحيوية عن طريق الفم. كما هو الحال مع مضادات العدوى الأخرى، قد يؤدي الاستخدام المطول إلى مقاومة المضادات الحيوية نتيجة فرط نمو الكائنات الدقيقة المسببة للأمراض.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من ارتفاع ضغط العين أو إذا كان لديك بالفعل ضغط مرتفع في العين بعد استخدام دواء الستيرويد للعين. أنت معرض لخطر الإصابة بهذا مرة أخرى إذا كنت تستخدم دوكريسا. إذا كنت تعاني من ارتفاع ضغط العين، يجب أن تخبر طبيبك.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من الجلوكوما.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من اضطراب في الرؤية أو تشوش الرؤية.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تستخدم مضادات الالتهاب غير الستيرويدية &nbsp;للعين (الأدوية غير الستيرويدية المضادة للالتهاب)، فراجع قسم &quot; استعمال الأدوية الأخرى مع دوكريسا&quot;.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من اضطراب يسبب ترقق أنسجة العين لأن العلاج بالستيرويد لفترات طويلة قد يسبب مزيدًا من الترقق والانثقاب المحتمل.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت مصابا بمرض السكر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات مهمة إذا كنت ترتدي العدسات اللاصقة</strong></p><p dir="RTL">-&nbsp;&nbsp; بعد جراحة إعتام عدسة العين ، يجب عدم ارتداء العدسات اللاصقة طوال فترة العلاج بدوكريسا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">-&nbsp;&nbsp; لا ينصح باستخدام دوكريسا للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا بسبب نقص البيانات المتعلقة بالسلامة والفعالية لهذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استعمال الأدوية الأخرى مع دوكريسا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي في الحالات الاتالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أي نوع آخر من قطرات العين أو مرهم العين قبل البدء في استخدام دوكريسا (انظر القسم 3 - كيفية استخدام دوكريسا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم مضادات الالتهاب غير الستيرويدية للعين (تستخدم ضد الألم والالتهابات في العين) مثل كيتورولاك وديكلوفيناك وبرومفيناك ونيبافيناك. قد يؤدي الاستخدام المتزامن للستيرويدات للعين ومضادات الالتهاب غير الستيروئيدية للعين إلى زيادة احتمالية حدوث مشاكل في شفاء العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم ريتونافير أو كوبيسيستات (المستخدم في علاج فيروس نقص المناعة البشرية)، فقد يؤدي ذلك إلى زيادة كمية الديكساميثازون في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم البروبينسيد (لعلاج النقرس)، السيميتيدين (لعلاج قرحة المعدة) والسيكلوسبورين (لمنع رفض زراعة الاعضاء) لأنها قد تغير امتصاص و استقلاب ليفوفلوكساسين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعاً أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فيجب عليك استشارة طبيبك أو الصيدلي للحصول استخدام هذا الدواء. لا ينبغي استخدام دوكريسا أثناء الحمل أو الرضاعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستعمال الألات</strong></p><p dir="RTL">إذا كنت تعاني من عدم وضوح الرؤية مؤقتًا بعد استخدام هذا الدواء لفترة قصيرة، فلا يجب عليك القيادة أو تشغيل الآلات حتى تصبح الرؤية لديك واضحة.</p><p dir="RTL"><strong>يحتوي دوكريسا على الفوسفات المتعادل</strong></p><p dir="RTL">يحتوي دوكريسا على 4.01 مجم فوسفات لكل مل، أي ما يعادل 0.12 مجم لكل قطرة. إذا كنت تعاني من ضرر شديد للطبقة الشفافة في مقدمة العين (القرنية)، فقد يتسبب الفوسفات في حالات نادرة جدًا في ظهور بقع غائمة على القرنية بسبب تراكم الكالسيوم أثناء العلاج. تحدث مع طبيبك الذي قد يصف لك علاجًا خالٍ من الفوسفات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي دوكريسا على كلوريد البنزالكونيوم</strong></p><p dir="RTL">يحتوي دوكريسا على 0.05 مجم كلوريد بنزالكونيوم لكل مل بما يعادل 0.0015 مجم لكل قطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب كلوريد البنزالكونيوم أيضًا في تهيج العين، خاصةً إذا كنت تعاني من جفاف العين أو اضطرابات في القرنية (الطبقة الشفافة في مقدمة العين). إذا شعرت بإحساس غير طبيعي بالعين أو لاذع أو ألم في العين بعد استخدام دوكريسا، فيجب عليك التحدث إلى طبيبك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا دوكريسا تمامًا كما يخبرك الطبيب أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">الجرعة الموصى بها هي قطرة واحدة في العين المصابة كل 6 ساعات. الجرعة القصوى هي 4 قطرات في اليوم. دورة العلاج الإجمالية المعتادة مع دوكريسا هي 7 أيام، تليها، إذا رأى الطبيب ذلك ضروريًا، 7 أيام أخرى من قطرات العين الستيرويدية.</p><p dir="RTL">سينصحك طبيبك بمدة استعمال القطرات.</p><p dir="RTL">إذا كنت تستعمل أي دواء آخر في عينك، فيجب أن تنتظر 15 دقيقة على الأقل بين استعمال الأنواع المختلفة من القطرات. يجب استخدام مراهم العين أخيرًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تعليمات الإستخدام:</strong></p><p dir="RTL">إذا كان ذلك ممكنًا، اطلب من شخص آخر وضع القطرات لك. اطلب منهم قراءة هذه التعليمات معك قبل وضع القطرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">1.&nbsp; اغسل يديك بعناية ( انظر الصورة 1).</p><p dir="RTL">2.&nbsp; افتح الزجاجة. قم بإزالة الطوق الفضفاض من الغطاء عند فتح الزجاجة لأول مرة.احرص على ألا يلمس طرف زجاجة القطارة عينك أو الجلد حول عينك أو أصابعك.</p><p dir="RTL">3.&nbsp; لف غطاء الزجاجة. أمسك الزجاجة باتجاه الأسفل بين إبهامك وأصابعك.</p><p dir="RTL">4.&nbsp; اسحب الجفن السفلي بإصبعك حتى يكون هناك &quot;جيب&quot; بين الجفن والعين. ثم ضع القطرة في هذا الموضع (الصورة 2).</p><p dir="RTL">5.&nbsp; قم بإمالة رأسك للخلف وجلب طرف الزجاجة بالقرب من العين واضغط على الزجاجة برفق من المنتصف واترك قطرة تسقط في عينك (الصورة 3). يرجى ملاحظة أنه قد يكون هناك تأخير لبضع ثوان بين الضغط وخروج القطرة. لا تضغط بشدة.</p><p dir="RTL">6.&nbsp; بعد استخدام دوكريسا، اضغط بإصبعك في زاوية عينك من الأنف. هذا يساعد على منع وصول الدواء إلى باقي الجسم (الصورة 4).</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Immagine_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:402pt;height:95pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/hmc103/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="536" height="127" src="file:///C:/Users/hmc103/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></p><p dir="RTL">اذا فقدت قطرة عينك ، حاول مرة أخرى. ثم ضع غطاء الزجاجة بإحكام مرة أخرى فور الاستخدام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت دوكريسا أكثر مما ينبغي</strong></p><p dir="RTL">إذا استخدمت المزيد من دوكريسا أكثر مما ينبغي، فيجب غسلها بالماء الدافئ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت استخدام دوكريسا</strong></p><p dir="RTL">إذا نسيت استخدام دوكريسا، فلا داعي للقلق، فقط استخدمه في أسرع وقت ممكن. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استخدام دوكريسا</strong></p><p>إذا توقفت عن استخدام دوكريسا في وقت مبكر عما هو مذكور بالتعليمات، فيجب أن تخبر طبيبك. إذا كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، فيجب أن تسأل الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب دوكريسا آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع. معظم الآثار الجانبية ليست خطيرة وتؤثر على العين فقط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرا جدا يمكن لدوكريسا أن تسبب تفاعلات تحسسية شديدة (ردود فعل تحسسية) مصحوبة بانتفاخ وضيق فى الحلق وصعوبة فى التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف عن استخدام دوكريسا واتصل بطبيبك على الفور في حالة ظهور أي من هذه الأعراض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث انتفاخ وتمزق في الأوتار عند الأشخاص الذين يتناولون الفلوروكينولونات عن طريق الفم أو الوريد، خاصة عند المرضى كبار السن والذين تم علاجهم بشكل متزامن بالكورتيكوستيرويدات. توقف عن تناول دوكريسا إذا كنت تعاني من ألم أو تورم في الأوتار (التهاب الأوتار).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تواجه أيضًا بعضًا من التأثيرات التالية أو كلها في العين :</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تظهر لدى أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ارتفاع ضغط العين.</p><p dir="RTL"><strong>شائعة</strong> (قد تظهر عند 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الراحة ، لاذع أو تهيج، حرقان، حكة في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية أو ضعفها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مخاط في العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تظهر عند 1 من كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستغرق شفاء القرنية وقتًا أطول من المتوقع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس غير طبيعي في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التمزق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف وتعب العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أكثر إشراقًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ أو احمرار (عيون محتقنة بالدم) في الغطاء الأمامي للعين (الملتحمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ أو احمرار في الجفن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية للضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصاق الجفون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تظهر عند 1 من بين 10000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حجم بؤبؤ العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدلي الجفون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيت الكالسيوم على سطح العين (تكلس القرنية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دموع وإحساس رملي في العين (اعتلال القرنية البلوري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في سمك سطح العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة على سطح العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقوب صغيرة على سطح العين (انثقاب القرنية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتفاخ سطح العين (استسقاء القرنية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين الذي يسبب الألم والاحمرار (التهاب القزحية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تواجه آثار جانبية في مناطق أخرى من جسمك بما في ذلك:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد تظهر عند 1 من كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير التذوق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد أو سيلان الأنف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong>(قد تظهر عند 1 من كل 1000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية مثل الطفح الجلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تظهر لدى 1 من بين 10000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في وظيفة الغدة الكظرية، والذي يمكن أن يظهر من خلال انخفاض نسبة السكر في الدم والجفاف وفقدان الوزن والشعور بالارتباك بشأن مكانك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الهرمونات: نمو شعر الجسم الزائد (خاصة عند النساء)، ضعف العضلات وهزالها، علامات تمدد أرجوانية على جلد الجسم، ارتفاع ضغط الدم، عدم انتظام أو انقطاع الدورة الشهرية، تغيرات في مستويات البروتين والكالسيوم في الجسم، توقف النمو عند الأطفال والمراهقين وتورم وزيادة الوزن في الجسم والوجه (تسمى متلازمة كوشينغ).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أي آثار جانبية، فعليك أن تتحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن التأثيرات الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة لا تتجاوز 30 درجة مئوية.</p><p dir="RTL">لا تستخدم دوكريسا بعد تاريخ انتهاء تاريخ الصلاحية المذكور على ملصق الزجاجة والكرتون بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">لا تستخدم دوكريسا إذا لاحظت أن الحلقة البلاستيكية حول الغطاء والرقبة مفقودة أو مكسورة قبل بدء استخدام زجاجة جديدة.</p><p dir="RTL">إبقاء الزجاجة مغلقة بإحكام. لمنع العدوى، ويجب التخلص من الزجاجة بعد 28 يومًا من فتحها لأول مرة، واستخدام زجاجة جديدة.</p><p dir="RTL">&nbsp;</p><p>لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات دوكريسا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي ديكساميثازون فوسفات الصوديوم و ليفوفلوكساسين مثل هيميهيدرات &nbsp;. يحتوي كل مليلتر من المحلول على 1 ملجم من ديكساميثازون.و 5 ملجم من الليفوفلوكساسين و</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي مونوهيدرات فوسفات ثنائي هيدروجين الصوديوم، فوسفات، ثنائي الصوديوم دوديكاهيدرات، سترات الصوديوم، كلوريد بنزالكونيوم، هيدروكسيد الصوديوم/حمض الهيدروكلوريك (كمنظم الرقم الهيدروجيني)، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:right"><strong>شكل دوكريسا وما هي محتويات العبوة</strong></p><p dir="ltr" style="text-align:right">دوكريسا هو محلول صافٍ أصفر مائل للخضرة خالي عمليًا من الجزيئات، حتى لو كانت القطرات المطرودة تبدو صافية وعديمة اللون. يتوافير في عبوة تحتوي على زجاجة بلاستيكية بيضاء بسعة 5 مل مع قطارة بيضاء. الزجاجة البلاستيكية مغلقة بغطاء لولبي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">سانتين أوي</p><p dir="RTL">نيتيهانكاتو 20، 33720تامبير، فنلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">توبيلوكس فارما إس.بي.أي</p><p dir="RTL">فيا كوستريكا 20/22، 00071 بوميزيا (أر إم)، ايطاليا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة مسؤولة عن إصدار التشغيلة</strong></p><p dir="RTL">سانتين أوي</p><p dir="RTL">كيلوبورتينكاتو 1، تامبير، 33100، فنلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في مايو 2021. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ducressa 1 mg/ml + 5 mg/ml, eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of eye drops, solution, contains dexamethasone sodium phosphate equivalent to 1 mg of dexamethasone and levofloxacin hemihydrate equivalent to 5 mg of levofloxacin.
One drop (about 30 microliter) contains about 0.03 mg of dexamethasone and 0.150 mg of levofloxacin.

Excipient(s) with known effect:
One ml of eye drops solution contains 0.05 mg benzalkonium chloride and one drop contains about 0.0015 mg of benzalkonium chloride.
One ml of eye drops solution contains 4.01 mg phosphates and one drop contains 0.12 mg phosphates.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution (eye drops).  
A clear, greenish-yellow solution practically free from particles with a pH of 7.0-7.4 and osmolality of 
270-330 mOsm/Kg. The expelled drops appear clear and colorless.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ducressa eye drops solution is indicated for prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>One drop instilled into the conjunctival sac after surgery every 6 hours. Duration of treatment is 7 days. Care should be taken not to discontinue therapy prematurely.</p><p>&nbsp;</p><p>If one dose is missed, treatment should continue with the next dose as planned.</p><p>&nbsp;</p><p>Re-evaluation of the patient to assess the need to continue the administration of corticosteroid eye drops as monotherapy is recommended after the completion of one week of therapy with Ducressa eye drops. The length of this treatment can depend on the patient&rsquo;s risk factors and outcome of surgery and must be determined by the doctor according to slit-lamp microscopic findings and depending on the severity of the clinical picture. A follow-up treatment with steroid eye drops should not normally exceed 2 weeks. However, care should be taken not to discontinue therapy prematurely.</p><p><em>&nbsp;</em></p><p><em>Paediatric population:</em></p><p>The safety and efficacy of Ducressa in children and adolescents below the age of 18 years have not been established. No data are available.</p><p>&nbsp;</p><p>Ducressa is not recommended for use in children and adolescents below the age of 18 years.</p><p><em>&nbsp;</em></p><p><em>Elderly patients:</em></p><p>No dosage adjustment in elderly patients is necessary.</p><p><em>&nbsp;</em></p><p><em>Use in renal/hepatic impairment</em></p><p>Ducressa has not been studied in patients with renal/hepatic impairment and Ducressa should therefore be used with caution in such patients.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Ocular use.</p><p>&nbsp;</p><p>One drop should be administered in the lateral canthus while applying pressure at the medial canthus to prevent drainage of the drops.</p><p>&nbsp;</p><p>Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures as this could cause injury to the eye.</p><p>&nbsp;</p><p>Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.</p><p>&nbsp;</p><p>Nasolacrimal occlusion by compression of lacrimal ducts may reduce systemic absorption.</p><p>&nbsp;</p><p>In case of concomitant treatment with other eye drops solutions, instillations should be spaced out by 15 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to active substance levofloxacin or to other quinolones, to dexamethasone, or to other steroids, or to any of the excipients listed in section 6.1;
•	Herpes simplex keratitis, varicella and other viral disease of the cornea and conjunctiva;
•	Mycobacterial infections of the eye caused by, but not limited to, acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium;
•	Fungal diseases of ocular structures;
•	Untreated purulent infection of the eye.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Ocular effects:</em></p><p>Ducressa is for ocular use only. Ducressa must not be injected sub-conjunctively. The solution should not be introduced directly into the anterior chamber of the eye.</p><p>&nbsp;</p><p>Prolonged use may induce antibiotic resistance with result of overgrowth of non-susceptible organisms, including fungi. If infection develops, the treatment should be discontinued and alternative therapy used.</p><p>Whenever clinical judgement dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</p><p>&nbsp;</p><p>Prolonged use of topical ophthalmic corticosteroids may result in ocular hypertension/glaucoma but this is unlikely when Ducressa is used for the recommended treatment period (7 days). In any case, it is advisable that the intraocular pressure be checked frequently. The risk of corticosteroid-induced increase in the intraocular pressure is increased in predisposed patients (e.g. diabetes).</p><p>&nbsp;</p><p>Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may be related to complications to cataract surgery, development of glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p><p>&nbsp;</p><p>Topical ophthalmic corticosteroids may slow corneal wound healing. Topical ocular NSAIDs are also known to slow or delay healing. Concomitant use of topical ocular NSAIDs and steroids may increase the potential for healing problems.</p><p>In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids.</p><p>&nbsp;</p><p><em>Systemic effects</em></p><p>Fluoroquinolones have been associated with hypersensitivity reactions, even following a single dose. If an allergic reaction to levofloxacin occurs, discontinue the medication.</p><p>&nbsp;</p><p>Tendon inflammation and rupture may occur with systemic fluoroquinolone therapy including levofloxacin, particularly in older patients and those treated concurrently with corticosteroids. Therefore, caution should be exercised and treatment with Ducressa should be discontinued at the first sign of tendon inflammation (see section 4.8).</p><p>&nbsp;</p><p>Cushing&rsquo;s syndrome and/or adrenal suppression associated with systemic absorption of ocular dexamethasone may occur after intensive or long-term continuous therapy in predisposed patients, including children and patients treated with CYP3A4 inhibitors (including ritonavir and cobicistat). In these cases, treatment should be progressively discontinued.</p><p>&nbsp;</p><p><em>Effects on Immune System</em></p><p>Prolonged use (generally observed within 2 weeks of treatment) may also result in secondary ocular infections (bacterial, viral, or fungal) due to suppression of host response or to the delay of their healing. In addition, topical ocular corticosteroids may promote, aggravate or mask signs and symptoms of eye infections caused by opportunistic microorganisms. Occurrence of these conditions is limited in case of short term corticosteroid treatment such as the one suggested for Ducressa.</p><p>&nbsp;</p><p><em>Excipients</em></p><p><em>Benzalkonium chloride:</em></p><p>Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.</p><p>&nbsp;</p><p>After cataract surgery patients should not wear contact lenses for the whole duration of therapy with Ducressa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>Since maximum plasma concentrations of levofloxacin and dexamethasone after ocular administration are at least 1000 times lower than those reported after standard oral doses, interactions with other products for systemic use are unlikely to be clinically relevant.</p><p>&nbsp;</p><p>The concomitant use of probenecid, cimetidine, or ciclosporin with levofloxacin altered some pharmacokinetic parameters of levofloxacin, but not to a clinically significant extent.</p><p>&nbsp;</p><p>Concomitant use of topical steroids and topical NSAIDs may increase the potential for corneal healing problems.</p><p>CYP3A4 inhibitors (including ritonavir and cobicistat) may decrease dexamethasone clearance resulting in increased effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>There are no or limited amount of data from the use of dexamethasone and levofloxacin in pregnant women. Corticosteroids cross the placenta. Prolonged or repeated corticosteroid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation, lower birth weight and risk for high blood pressure, vascular disorders and insulin resistance in the adulthood. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Studies in animals with corticosteroids have shown reproductive toxicity and teratogenic effects (including cleft palate; see section 5.3).</p><p>Since a relevant systemic corticosteroid exposure cannot be excluded after ocular administration, treatment with Ducressa is not recommended during pregnancy, and especially during the first three months, should only take place after a careful benefit-risk assessment.&nbsp;</p><p>&nbsp;</p><p><em>Breastfeeding</em></p><p>Systemic corticosteroids and levofloxacin are excreted into human milk. No data are available, to indicate whether relevant amounts of dexamethasone are transferred into human breast milk and which are capable of producing clinical effects in the infant. A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Ducressa therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><em>Fertility</em></p><p>Systemically administered corticosteroids may impair male and female fertility by influencing hormonal secretion of the hypothalamus and pituitary gland as well as gametogenesis in testes and ovaries. It is unknown if dexamethasone impairs human fertility after ocular use.</p><p>&nbsp;</p><p>Levofloxacin caused no impairment of fertility in rats at exposures considerably in excess of the maximum human exposure after ocular administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any eye drops, temporarily blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs, the patient must wait until the vision is clear before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile </em></p><p>In clinical studies, 438 patients have been treated with Ducressa. No serious adverse reactions occurred. The most commonly reported non-serious adverse reactions are eye irritation, ocular hypertension and headache.</p><p>&nbsp;</p><p><em>Tabulated list of adverse reactions </em></p><p>The following adverse reactions have been reported with Ducressa during clinical trials that enrolled patients after cataract surgery (within each frequency grouping, adverse reactions are presented in order of decreasing frequency).</p><p>&nbsp;</p><p>The frequency of possible adverse reactions listed below is defined using the following convention:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>&ge; 1/10</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&ge; 1/100 to &lt;1/10</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&ge;1/1,000 to &lt;1/100</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>&ge;1/10,000 to &lt;1/1,000</p></td></tr><tr><td style="vertical-align:top"><p>very rare</p></td><td style="vertical-align:top"><p>&le;1/10,000</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>Frequency cannot be estimated from the available data</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Ducressa (levofloxacin/dexamethasone combination)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Headache, dysgeusia.</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eye irritation, abnormal sensation in eye, ocular hypertension.</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pruritus.</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Intraocular pressure increased. (*)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>(*) &gt; 6 mmHg that means significant intraocular pressure increase</p></td></tr></tbody></table><p>&nbsp;</p><p>Adverse reactions that have been seen with either of the ophthalmic active substances (levofloxacin or dexamethasone), and may potentially occur also with Ducressa are listed below:</p><p><strong>Levofloxacin </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Extra-ocular allergic reactions, including skin rash.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Anaphylaxis.</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Ocular burning, decreased vision and mucous strand.&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Lid matting, chemosis, conjunctival papillary reaction, lid oedema, ocular discomfort, ocular itching, ocular pain, conjunctival hyperaemia, conjunctival follicles, ocular dryness, lid erythema, and photophobia.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon:</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Laryngeal oedema.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Dexamethasone</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Increase of the intraocular pressure.*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Discomfort*, irritation*, burning*, stinging*, itching* and blurred vision.*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Allergic and hypersensitivity reactions, delayed wound healing, posterior capsular cataract*, opportunistic infections, glaucoma.*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Conjunctivitis, mydriasis, ptosis, corticosteroid-induced uveitis, corneal calcifications, crystalline keratopathy, changes in corneal thickness*, corneal oedema, corneal ulceration and corneal perforation.</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Face oedema.</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cushing&rsquo;s syndrome, adrenal suppression.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* see section Description of selected adverse reactions</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Description of selected adverse reactions&nbsp;</p><p><em>Increase of intraocular pressure</em></p><p>Increase of the intra-ocular pressure (IOP) and glaucoma may occur. Prolonged use of corticosteroid treatment may result in ocular hypertension/glaucoma (especially for patients with previous high IOP induced by steroids or with pre-existing high IOP or glaucoma). Children and elderly patients may be particularly susceptible to steroid-induced IOP rise (see section 4.4). Diabetics are also more prone to develop subcapsular cataracts following prolonged topical steroid administration.</p><p>&nbsp;</p><p><em>Post procedural adverse reactions</em></p><p>Ocular disorders (e.g. corneal oedema, eye irritation, abnormal sensation in the eye, lacrimation increased, asthenopia, corneal disorder, dry eye, eye pain, ocular discomfort, uveitis, blurred vision, visual brightness, conjunctivitis) and nausea have been reported during clinical trials. &nbsp;These reactions are usually mild and transient and are assessed to be related to the cataract surgery itself.</p><p>&nbsp;</p><p><em>Possible adverse reactions related to cornea</em></p><p>In diseases causing thinning of the cornea, topical use of steroids could lead to cornea perforation in some cases (see section 4.4).</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.</p><p><em>&nbsp;</em></p><p><em>Additional adverse reactions that have been observed with prolonged use of the active substance levofloxacin and may potentially occur also with Ducressa</em></p><p>Ruptures of the shoulder, hand, Achilles, or other tendons that required surgical repair or resulted in prolonged disability have been reported in patients receiving systemic fluoroquinolones. Studies and post marketing experience with systemic quinolones indicate that a risk of these ruptures may be increased in patients receiving corticosteroids, especially geriatric patients and in tendons under high stress, including Achilles tendon (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;</p><p>For <strong>United Arab Emirates</strong>, you can report any side effects through the Ministry of health and prevention:</p><p>Pharmacovigilance and Medical Device Section</p><p>P.O.Box : 1853</p><p>Tel: 800011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health and Prevention</p><p>Dubai, U.A.E</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The total amount of levofloxacin and dexamethasone 21-Phosphate in vial of Ducressa is too small to induce toxic effects after an accidental intake.</p><p>In the case of topical overdose, the treatment should be stopped. In case of prolonged irritation, the eye(s) should be rinsed with sterile water.</p><p>&nbsp;</p><p>The symptomatology due to accidental ingestion is not known. The physician may consider gastric lavage or emesis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-inflammatory agents and anti-infectives in combination, corticosteroids and anti-infectives in combination.</p><p>&nbsp;</p><p>ATC code: S01C A01</p><p>&nbsp;</p><p>Ducressa is a fixed dose combination of two active substances: levofloxacin and dexamethasone.</p><p><strong>&nbsp;</strong></p><p><strong>Levofloxacin:</strong></p><p><u>Mechanism of action:</u></p><p>Levofloxacin, the active L-isomer of ofloxacin, is a fluoroquinolone antibacterial agent, that inhibits bacterial type II topoisomerases&mdash;DNA gyrase and topoisomerase IV. Levofloxacin preferentially targets DNA gyrase in Gram negative bacteria and topoisomerase IV in Gram positive bacteria. The spectrum of activity against ocular pathogens includes aerobic Gram-positive microorganisms (e.g. <em>S. aureus </em>MSSA<em>, S. pyogenes, S. pneumoniae, </em>viridans group streptococci), aerobic Gram-negative bacteria (e.g. <em>E. coli, H. influenzae, </em><em>M. catarrhalis,</em><em> P. aeruginosa</em> community isolates), other organisms (e.g. <em>Chlamydia trachomatis</em>).</p><p><u>&nbsp;</u></p><p><u>Mechanisms of resistance</u></p><p>Bacterial resistance to levofloxacin can develop primarily due to two main mechanisms, namely a decrease in the intrabacterial concentration of a drug, or alterations in a drug&#39;s target enzymes. Target site alteration results from mutations in the chromosomal genes encoding the DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE; grlA and grlB in Staphylococcus aureus). Resistance due to low intrabacterial drug concentration follows either from altered outer-membrane porins (OmpF) leading to reduced entry of fluoroquinolones in Gram-negative bacteria or from efflux pumps. Efflux-mediated resistance has been described in pneumococci (PmrA), staphylococci (NorA), anaerobes, and Gram negative bacteria. Finally, plasmid-mediated resistance to quinolones (determined by the qnr gene) has been reported in Klebsiella pneumoniae and in E.coli.</p><p><u>&nbsp;</u></p><p><u>Cross-resistance</u></p><p>Cross-resistance between fluoroquinolones may occur. Single mutations may not result in clinical resistance, but multiple mutations generally do result in clinical resistance to all drugs within the fluoroquinolone class. Altered outer-membrane porins and efflux systems may have a broad substrate specificity, targeting several classes of antibacterial agents and leading to multiresistance.</p><p><u>&nbsp;</u></p><p><u>Susceptibility testing interpretive criteria</u></p><p>There are no interpretive criteria.</p><p>&nbsp;</p><p><strong>Dexamethasone:</strong></p><p><u>Mechanism of action:</u></p><p>Corticosteroids like dexamethasone&nbsp; &nbsp;suppress vascular endothelial cell adhesion molecules, cyclooxygenase I or II, and cytokine expression. This action culminates in a reduced expression of proinflammatory mediators and the suppression of adhesion of circulating leukocytes to the vascular endothelium, thereby preventing their migration into inflamed ocular tissue. Dexamethasone has marked anti-inflammatory activity with reduced mineralocorticoid activity compared with some other steroids and is one of the most potent anti-inflammatory agents.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy:</u></p><p>The efficacy of Ducressa has been investigated in a controlled study to evaluate the non-inferiority of the Ducressa vs. a standard treatment with a commercial formulation of tobramycin (0.3%) and dexamethasone (0.1%) eye drops for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. The Investigator in charge of evaluating study parameters was blinded to treatment assignment. Patients who completed their cataract surgery without complications were assigned to Ducressa eye drops, 1 drop 4 times a day for 7 days, followed by dexamethasone 0.1% eye drops, 1 drop 4 times a day, for an additional 7 days, or to reference tobramycin + dexamethasone eye drops, 1 drop 4 times a day for 14 days.</p><p>Data of efficacy were available in 395 patients given Ducressa and in 393 patients given the reference product after cataract surgery. After 14 days of treatment, the proportion of patients with no signs of inflammation (primary endpoint of the study) in the Ducressa followed by dexamethasone group compared to the tobramycin + dexamethasone group was 95.19% vs. 94.91%, respectively. The difference between the two proportions was 0.0028 (95% CI: [-0.0275; 0.0331]), which demonstrated the non-inferiority of the test vs. reference treatment regimen. No occurrence of endophthalmitis was reported during the study for either group. Signs of anterior chamber inflammation were absent in Ducressa arm in 73.16% at day 4 and in 85.57% of patients at day 8 after surgery. In tobramycin + dexamethasone arm, signs of anterior chamber inflammation were absent in 76.84% at day 4 and in 86.77% of patients at day 8. Conjunctival hyperemia was already absent at day 4 in 85.75% in Ducressa treatment arm vs. 82.19% in tobramycin + dexamethasone arm, respectively. The safety profile was similar in both groups</p><p><strong>&nbsp;</strong></p><p>Pediatric population</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Ducressa in all subsets of the paediatric population for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery (see section 4.2 for information on pediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ocular instillation of Ducressa results in absorption of both actives to the ocular tissues and, at a much lower extent, to the systemic circulation.</p><p>After instillation to rabbit eyes, the plasma concentrations of levofloxacin increase with the dose after both single and repeated administration. Low levels of dexamethasone sodium phosphate are measured in plasma. In fact, dexamethasone sodium phosphate is rapidly metabolised <em>in vivo</em> to dexamethasone, which is the active metabolite. Dexamethasone exposure increases with the dose and after repeated doses a minor accumulation of both levofloxacin and dexamethasone is evident. Both levofloxacin and dexamethasone levels in ocular tissues (aqueous humour, cornea and conjunctiva) result to be higher than the maximum plasma levels after single and repeated doses. In particular, after 28-day treatment levofloxacin and dexamethasone levels in ocular tissues are 50 to 100-fold and 3 to 4-fold higher than the Cmax in plasma, respectively.</p><p>One-hundred-twenty-five patients undergoing cataract surgery have been randomized to 3 groups: levofloxacin, dexamethasone and Ducressa. One drop of each drug was administered 90 and 60 minutes before limbal paracentesis. The mean of the observed values for the concentration of levofloxacin was equal to 711.899 ng/mL (95% CI: 595.538; 828.260) in the Ducressa group compared to 777.307 ng/mL (95% CI: 617.220; 937.394) when levofloxacin was administered alone. The concentrations of levofloxacin in the aqueous humour are well above the minimum inhibitory concentrations for the ocular pathogens in levofloxacin&rsquo;s spectrum of activity.</p><p>When Ducressa was administered dexamethasone reached an aqueous humour concentration of 11.774 ng/mL (95% CI: 9.812; 13.736) compared to 16.483 ng/mL (95% CI: 13.736; 18.838) when dexamethasone was administered alone.</p><p>Both levofloxacin and dexamethasone are eliminated via urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose ocular toxicity studies with the levofloxacin/dexamethasone fixed dose combination for up to 28&nbsp;days in rabbits revealed systemic toxicities attributable to exaggerated pharmacological effects of dexamethasone (focal tubular cell necrosis and glomerulopathy with necrosis and/or hyaline depositions in kidneys, hepatic hypertrophy with intracellular hyaline inclusions and single cell necrosis, atrophy of adrenal gland cortex and lymphocyte decreases due to atrophy of spleen, thymus and lymph nodes).</p><p>Such effects were observed only at about 3-fold higher exposures than achieved at the maximum recommended human ocular dose, indicating little relevance to clinical use.</p><p>Gyrase inhibitors have been shown to cause growth disorders of weight bearing joints in animal studies. In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs after high oral doses.</p><p>&nbsp;</p><p><u>Genotoxicity and carcinogenicity</u></p><p>Dexamethasone and levofloxacin did not reveal any clinically relevant genotoxic or carcinogenic potential.</p><p><u>&nbsp;</u></p><p><u>Reproductive toxicity:</u></p><p>Levofloxacin did not influence fertility and only impaired embryo-foetal development in animals at exposures, considerably in excess of those achievable at the recommended ocular therapeutic dose in humans. &nbsp;Topical and systemic administration of dexamethasone impaired male and female fertility and induced teratogenic effects including formation of cleft palate, intra-uterine growth retardation and foetal mortality. Peri- and postnatal toxicity of dexamethasone was also observed.</p><p><u>&nbsp;</u></p><p><u>Phototoxic potential:</u></p><p>Studies in the mouse after both oral and intravenous dosing showed levofloxacin to have phototoxic activity only at very high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium dihydrogen phosphate monohydrate</p><p>Disodium phosphate dodecahydrate</p><p>Sodium citrate</p><p>Benzalkonium chloride</p><p>Sodium hydroxide /Hydrochloric acid (for pH adjustment)&nbsp;</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Discard within 28 days after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml Low-Density Polyethylene (LDPE) bottle, with a LDPE dropper tip and a High-Density Polyethylene (HDPE) screw cap.</p><p>Pack sizes: 1 bottle x 5 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused antibiotic or antibiotic residual solution as well as materials that have been used for administration should be disposed in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Santen Oy
Tampere, Finland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>